EQT has agreed to acquire a majority stake in CluePoints, a cloud-based software provider specializing in Risk-Based Quality Management for clinical trials, alongside minority stakeholders Summit Partners and Clinimetrics SA.

Information on the Target

CluePoints is a leading software provider specializing in Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials. Founded in 2012 and headquartered in Belgium, CluePoints utilizes advanced statistics and machine learning to enhance the integrity and compliance of clinical trial data. With a robust algorithmic framework developed over a decade of experience in clinical trials, the platform effectively supports pharmaceutical and biotech companies, contract research organizations, and other stakeholders. CluePoints currently serves more than 9,500 users and has contributed to de-risking over 1,600 studies and identifying more than 142,000 issues for prominent clients among the top 20 largest pharmaceutical companies worldwide.

Industry Overview in Belgium

The pharmaceutical and biotechnology industries in Belgium are experiencing unprecedented growth, driven by advancements in technology, increasing research and development expenditure, and regulatory demands focused on patient safety and data integrity. The adoption of Risk-Based Quality Management software is on the rise, characterized by a growing need to manage the increasing complexity of clinical trial data. This trend is propelled by the emphasis on improving data quality through sophisticated oversight mechanisms that mitigate risks during the drug development process.

In recent years, Belgium has established itself as a hub for innovative healthcare solutions, particularly in the areas of pharmaceutical research and biotech development. As the industry evolves, companies are continuously seeking cutting-edge technologi